# OPB-101

Source: https://onco.cc/drugs/opb-101/  
OnCo record `opb-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OPB-101 is an experimental autologous CAR T-cell therapy from Outpace Bio, in phase 1 trials for platinum-resistant ovarian cancer; its current status is not stated.

## Summary

OPB-101 is an autologous CAR T-cell therapy from Outpace Bio. Autologous mesothelin CAR T cells that switch on a designed IL-2 cytokine (OUTSMART) only when they meet the target antigen. Its furthest stage is phase 1, for platinum-resistant ovarian cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07030907 terminated, reason "Business decision"; OPB-101 is no longer on the company pipeline page (checked 3 Nov 2026). No source states it is discontinued. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: OPB-101
- Modality: Autologous CAR T-cell therapy
- Mechanism: Autologous mesothelin CAR T cells that switch on a designed IL-2 cytokine (OUTSMART) only when they meet the target antigen.

## Sources

- Outpace Bio: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07030907
- Outpace Bio: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07030907
- ClinicalTrials.gov: trials of OPB-101: https://clinicaltrials.gov/search?intr=OPB-101

## Connected records

- cancers: [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- targets: [Mesothelin](https://onco.cc/targets/mesothelin/)
- companies: [Outpace Bio](https://onco.cc/companies/outpace-bio/)
- trials: [A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07030907/)

---
JSON: https://onco.cc/api/v1/entities/opb-101.json